Navigation Links
Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
Date:8/3/2011

WAYLAND, Mass., Aug. 3 , 2011) /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The contract totals $2.9 million over 2 years provided that key milestones are achieved. Should Avaxia's program meet its anticipated endpoints at the end of this contract, the company hopes to pursue future opportunities with BARDA.  

Dr. Barbara Fox, Avaxia's CEO, commented, "We are very pleased to receive this contract and are proud to be working on this program related to our country's national defense. With this funding, we will be advancing our oral antibody product through the key efficacy studies needed to support the product's use as a nuclear threat countermeasure. This contract will permit us to complete the pre-clinical pharmacology studies for this potential therapy. We look forward to working with BARDA to develop a novel drug that can effectively protect the gastrointestinal tract from radiation damage.

This award provides Avaxia with a new drug development program that is of significant benefit to the company.  Besides providing the company with additional scientific infrastructure, the research to be conducted on this therapeutic will contribute to and support our innovative technology platform and bolster work being done in the related field of inflammatory bowel disease.  Also, should the project meet its targets, the manufacturing and sales of a radiation mitigation drug will increase the commercial opportunities for the company."

About BARDA:  The Biomedical Advanced Research and Development Authority (BARDA), is part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.  BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, stockpile acquisition, innovation, and manufacturing infrastructure building of the necessary vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health medical emergencies including chemical, biological, radiological, and nuclear threats, and pandemic influenza, and emerging infectious diseases. For additional information, visit www.hhs.gov/aspr.

About Avaxia Biologics, Inc.:  Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, oral mucositis, celiac disease, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Canada Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. China Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
5. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
9. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... The pen needles market is projected to ... billion in 2016, growing at a CAGR of 11.2% ... Over the years, the pen needles market has witnessed ... growing demand for safety injections in the healthcare industry. ... pen needles with an aim to reduce pain, increase ...
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million people ... from the epidemic of diabetes. 1 However, nearly ... elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... complications, including cardiovascular events. If left untreated, hyperglycemia can ... eye disease or blindness. 3 As ...
(Date:12/6/2016)... Fla. , Dec. 6, 2016 With opioids commonly ... newcomer in the prescription drug market that has led to nationwide ... approximately seven to eight times stronger than heroin or morphine, resulting ... ... Suzanne Smolkin , vice president, clinical operations, Behavioral Health for HMC ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... One of two ... of the securement tape is painful for her. "This is why the co-inventor and ... heads," she said. , They then created a prototype of the patent-pending AV-AIR, a ...
(Date:12/7/2016)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... declared on her radio program in November 2016 the need to educate people about ... leaders in corporate America, they are trying to take advantage of successful algorithms and ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is condemning "scam operations" carried out by unethical locksmith companies and is urging ... to a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “Tomorrow Trump ... Donald Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes ... to do as much as she can for this country. , Nancy attributes her ...
Breaking Medicine News(10 mins):